Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609423 | 0.91 | P2RX4 (0.49) | P2RX4MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9609400 | 0.85 | ALDH1A1 (0.59) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL9609418 | 0.84 | P2RX4 (0.47) | P2RX4MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9609422 | 0.83 | P2RX4 (0.58) | P2RX4MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9609395 | 0.81 | HTT (0.48) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL9609425 | 0.81 | HDAC6 (0.41) | P2RX4SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL9609426 | 0.80 | P2RX4 (0.45) | P2RX4MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9609419 | 0.80 | P2RX4 (0.47) | P2RX4MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28041337 | 0.78 | P2RX4 (0.86) | P2RX4MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9609401 | 0.78 | NPC1 (0.48) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073854-B2 | Aromatic sulfonium salt compound | ADEKA CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20120136155-A1 | AROMATIC SULFONIUM SALT COMPOUND | ADEKA CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136155-A1 | AROMATIC SULFONIUM SALT COMPOUND | F12, ASIC1, SPIN1 | P2RX4 1078/4885MEN1 1116/4885KMT2A 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.